AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Uptake of the Childhood Live Attenuated Influenza Vaccine (LAIV) and Influenza-related Healthcare Resource Use in England During the 2012 to 2022 Flu Seasons; a Retrospective, Observational Study in the CPRD and HES Databases
Completed
- Conditions
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12775880
- Registration Number
- NCT06077045
- Locations
- 🇬🇧
CPRD, London, United Kingdom
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT06075095
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain
Recruiting
- Conditions
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT06068049
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).
Phase 3
Recruiting
- Conditions
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT06067828
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
Completed
- Conditions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 628
- Registration Number
- NCT06056778
- Locations
- 🇷🇺
Research Site, Voronezh, Russian Federation
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
Phase 2
Completed
- Conditions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 116
- Registration Number
- NCT06057064
- Locations
- 🇷🇺
Research Site, St Petersburg, Russian Federation
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT06053424
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs.
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 37
- Registration Number
- NCT06046534
- Locations
- 🇬🇧
Research Site, Leeds, United Kingdom
A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 33
- Registration Number
- NCT06042049
- Locations
- 🇯🇵
Research Site, Yokohama-shi, Japan
A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
Completed
- Conditions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT06039683
- Locations
- 🇦🇪
Research Site, Al Ain, United Arab Emirates
© Copyright 2024. All Rights Reserved by MedPath